ANGLE PLC (LON:AGL) has announced the appointment of leading NHS prostate cancer surgeon Greg Shaw as a scientific advisor to the company.
The AIM-listed firm said, joining its already established Scientific Advisory Board, Shaw brings significant additional prostate cancer and UK NHS clinical experience.
The company said Shaw is a consultant urological surgeon at University College Hospital in London and is a clinical academic with a strong interest in prostate cancer diagnostics and treatment.
ANGLE said Shaw leads several research programmes focused on current weaknesses in the way prostate cancer is treated and is an expert in robotic surgery with a high case volume. He is known for his innovative approach and commitment to quality assurance.
Andrew Newland, founder and chief executive of ANGLE, said: “As we prepare to extend our prostate cancer work, we are delighted that we will be able to benefit from Greg Shaw’s extensive experience in this area.”
He added: “Greg’s understanding of current clinical practice in the UK and the key areas of medical need that liquid biopsy can address will help us to position Parsortix clinical applications for prostate cancer in the future.”